
Pieris Pharma (PIRS) Earnings Dates & Reports
Pieris Pharma (PIRS) Most Recent Earnings
Report Date
Period EndingQ4 2023
Est. EPS-$0.12
Actual EPS-$0.04
EarningsBeat
Pieris Pharma (PIRS) Earnings
View the latest Pieris Pharma (PIRS) earnings report, listen to the earnings call, and analyze historical earnings performance with AI-powered insights.
Start investing in Pieris Pharma (PIRS)
Order type
Buy in
Order amount
Est. shares
0 shares
Pieris Pharma (PIRS) Earnings per Share (EPS) History
Signup for full accessBrowse free
Pieris Pharma (PIRS) Latest Earnings
The value each PIRS share was expected to gain vs. the value each share gained.
Pieris Pharma (PIRS) reported its most recent earnings on for Q4 2023, posting earnings per share (EPS) of -$0.04. This exceeded analysts' expectations of -$0.12 by 66.67%, marking a Beat.
For comparison, Pieris Pharma reported EPS of -$0.11 in the same quarter last year.
The company is expected to announce its next earnings report on , with analysts projecting an EPS of $0.
Pieris Pharma (PIRS) Earnings History
Pieris Pharma (PIRS) Earnings Related Price Changes
Earnings announcements may impact a stock’s price. This table highlights the Pieris Pharma’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.
| Report date | Price 1D before | Price 1D after | Change |
|---|---|---|---|
| — | — | — | |
| — | — | — | |
| — | — | — | |
| — | — | — |
Pieris Pharma (PIRS) Earnings FAQs
Pieris Pharma (PIRS) last reported earnings on Mar 29, 2024 for Q4 2023, posting an EPS of -$0.04, which Beat the estimate of -$0.12 by 66.67%.
For Q4 2023, Pieris Pharma (PIRS) reported an EPS of -$0.04, exceeding analysts' estimate of -$0.12 by 66.67%.
For Q4 2023, Pieris Pharma (PIRS) Beat expectations with an actual EPS of -$0.04 vs. an estimated EPS of -$0.12.
Following the last earnings report on Mar 29, 2024, Pieris Pharma (PIRS)'s stock price moved — from — to —.
The next Pieris Pharma (PIRS) earnings call is scheduled for Nov. 13, 2024, where executives will discuss financial results and outlook.